PT3328888T - Anticorpos anti-psma, moléculas biespecíficas de ligação a antigénio que ligam psma e cd3, e seus usos - Google Patents
Anticorpos anti-psma, moléculas biespecíficas de ligação a antigénio que ligam psma e cd3, e seus usosInfo
- Publication number
- PT3328888T PT3328888T PT167480235T PT16748023T PT3328888T PT 3328888 T PT3328888 T PT 3328888T PT 167480235 T PT167480235 T PT 167480235T PT 16748023 T PT16748023 T PT 16748023T PT 3328888 T PT3328888 T PT 3328888T
- Authority
- PT
- Portugal
- Prior art keywords
- psma
- binding molecules
- bispecific antigen
- bind
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199823P | 2015-07-31 | 2015-07-31 | |
| US201562222590P | 2015-09-23 | 2015-09-23 | |
| US201662351823P | 2016-06-17 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3328888T true PT3328888T (pt) | 2023-01-05 |
Family
ID=56610023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167480235T PT3328888T (pt) | 2015-07-31 | 2016-07-29 | Anticorpos anti-psma, moléculas biespecíficas de ligação a antigénio que ligam psma e cd3, e seus usos |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10179819B2 (pt) |
| EP (2) | EP4183805A1 (pt) |
| JP (2) | JP6975707B2 (pt) |
| KR (1) | KR20180042272A (pt) |
| CN (1) | CN108137700B (pt) |
| AR (1) | AR106570A1 (pt) |
| AU (1) | AU2016302928B2 (pt) |
| CA (1) | CA2994245A1 (pt) |
| DK (1) | DK3328888T5 (pt) |
| EA (1) | EA038603B1 (pt) |
| ES (1) | ES2935120T3 (pt) |
| FI (1) | FI3328888T3 (pt) |
| HK (1) | HK1255971A1 (pt) |
| HR (1) | HRP20230237T1 (pt) |
| HU (1) | HUE061419T2 (pt) |
| JO (1) | JOP20160154B1 (pt) |
| LT (1) | LT3328888T (pt) |
| MD (1) | MD3328888T2 (pt) |
| PL (1) | PL3328888T3 (pt) |
| PT (1) | PT3328888T (pt) |
| RS (1) | RS63991B1 (pt) |
| SI (1) | SI3328888T1 (pt) |
| TW (1) | TWI728990B (pt) |
| WO (1) | WO2017023761A1 (pt) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738132B2 (en) | 2013-01-14 | 2020-08-11 | Xencor, Inc. | Heterodimeric proteins |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
| TWI744247B (zh) | 2015-08-28 | 2021-11-01 | 美商亞穆尼克斯製藥公司 | 嵌合多肽組合體以及其製備及使用方法 |
| ES2901133T3 (es) * | 2015-09-23 | 2022-03-21 | Regeneron Pharma | Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos |
| KR102466763B1 (ko) | 2016-04-13 | 2022-11-11 | 오리맵스 리미티드 | 항- psma 항체 및 이의 용도 |
| EP3475304B1 (en) | 2016-06-28 | 2022-03-23 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| MA47325A (fr) | 2017-01-20 | 2019-11-27 | Juno Therapeutics Gmbh | Conjugués de surface cellulaire et compositions cellulaires et méthodes associées |
| EP3607319A1 (en) | 2017-04-07 | 2020-02-12 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| AU2018280681A1 (en) | 2017-06-05 | 2019-12-05 | Numab Therapeutics AG | Novel anti-CD3 antibodies |
| BR112020004977A2 (pt) * | 2017-09-29 | 2020-10-06 | Regeneron Pharmaceuticals, Inc. | moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos |
| JP7361727B2 (ja) | 2018-05-24 | 2023-10-16 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｓｍａ結合剤及びその使用 |
| US11548947B2 (en) | 2018-06-21 | 2023-01-10 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof |
| CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| KR20210111243A (ko) | 2018-10-31 | 2021-09-10 | 리제너론 파아마슈티컬스, 인크. | 단백질을 식별 및 정량화하는 방법 및 시스템 |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| CN116178547A (zh) * | 2019-02-22 | 2023-05-30 | 武汉友芝友生物制药股份有限公司 | Cd3抗原结合片段及其应用 |
| CN113677701A (zh) * | 2019-03-29 | 2021-11-19 | 豪夫迈·罗氏有限公司 | 产生亲合结合多特异性抗体的方法 |
| CA3136892A1 (en) * | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methods of treating renal cancer with an anti- psma/cd3 antibody |
| JP2022529985A (ja) | 2019-04-19 | 2022-06-27 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｐｓｍａ／ｃｄ３抗体で前立腺癌を治療する方法 |
| CA3140816A1 (en) | 2019-06-14 | 2020-12-17 | Nathan Trinklein | Multispecific heavy chain antibodies binding to cd22 and cd3 |
| JP2022537269A (ja) | 2019-06-21 | 2022-08-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| WO2020257681A1 (en) * | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
| JP2022540385A (ja) * | 2019-07-02 | 2022-09-15 | テリックス インターナショナル ピーティーワイ リミテッド | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
| AU2020320420A1 (en) * | 2019-07-26 | 2022-03-17 | Ixaka France | Aptamer-based multispecific therapeutic agents |
| JP2022547081A (ja) * | 2019-09-06 | 2022-11-10 | シンフォジェン・アクシェセルスケープ | 抗ｃｄ７３抗体 |
| EP4087613A1 (en) * | 2020-01-06 | 2022-11-16 | Cytomx Therapeutics Inc. | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| WO2021231976A1 (en) * | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| MX2023006817A (es) | 2020-12-09 | 2023-08-14 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
| MX2023008909A (es) * | 2021-01-28 | 2023-10-23 | Janssen Biotech Inc | Proteínas de unión a psma y usos de estas. |
| JP2024506831A (ja) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイトカイン放出症候群を治療するための組成物及び方法 |
| AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| JP2024517701A (ja) | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 組換え生産タンパク質の低分子量種を低減させる方法 |
| WO2023051656A1 (zh) * | 2021-09-30 | 2023-04-06 | 贝达药业股份有限公司 | 双特异性抗体及其应用 |
| US20230265218A1 (en) | 2022-02-23 | 2023-08-24 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| WO2023183231A1 (en) | 2022-03-21 | 2023-09-28 | Amgen Inc. | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023224912A1 (en) | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2024035953A2 (en) * | 2022-08-11 | 2024-02-15 | Adicet Therapeutics, Inc. | Affinity binding entities directed to psma and methods of use thereof |
| WO2024118940A1 (en) * | 2022-12-01 | 2024-06-06 | Twist Bioscience Corporation | Anti-psma antibodies and uses thereof |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017981A (en) | 1911-05-29 | 1912-02-20 | Auguste Arsene Lemetre | Electroplating with zinc. |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| DE69735294T2 (de) * | 1996-03-25 | 2006-09-21 | Medarex Inc. | Spezifische monoklonale antikörper für die extrazelluläre domäne von protasta-spezifischem membranantigen |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| AU2002318169B2 (en) | 2001-06-01 | 2007-10-18 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| EP2363404B8 (en) * | 2001-10-23 | 2016-12-07 | PSMA Development Company L.L.C. | PSMA antibodies |
| EP1629011B1 (en) | 2003-05-31 | 2010-01-13 | Micromet AG | Human anti-human cd3 binding molecules |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| DK1851250T3 (da) * | 2005-02-18 | 2012-07-09 | Medarex Inc | Humant monoklonalt antistof mod prostataspecifikt membranantigen (psma) |
| PL2041177T3 (pl) | 2006-06-02 | 2012-09-28 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| SG194398A1 (en) * | 2008-10-01 | 2013-11-29 | Amgen Res Munich Gmbh | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| EP3916011A1 (en) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| RU2724663C2 (ru) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| JP5759618B2 (ja) * | 2012-03-30 | 2015-08-05 | 川崎重工業株式会社 | 水力発電装置 |
| AU2013249267A1 (en) * | 2012-04-20 | 2014-10-23 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-07-25 JO JOP/2016/0154A patent/JOP20160154B1/ar active
- 2016-07-28 TW TW105123831A patent/TWI728990B/zh active
- 2016-07-29 HR HRP20230237TT patent/HRP20230237T1/hr unknown
- 2016-07-29 FI FIEP16748023.5T patent/FI3328888T3/fi active
- 2016-07-29 PL PL16748023.5T patent/PL3328888T3/pl unknown
- 2016-07-29 CA CA2994245A patent/CA2994245A1/en active Pending
- 2016-07-29 SI SI201631655T patent/SI3328888T1/sl unknown
- 2016-07-29 DK DK16748023.5T patent/DK3328888T5/da active
- 2016-07-29 AU AU2016302928A patent/AU2016302928B2/en active Active
- 2016-07-29 EP EP22203815.0A patent/EP4183805A1/en active Pending
- 2016-07-29 KR KR1020187005964A patent/KR20180042272A/ko not_active Application Discontinuation
- 2016-07-29 ES ES16748023T patent/ES2935120T3/es active Active
- 2016-07-29 CN CN201680058001.9A patent/CN108137700B/zh active Active
- 2016-07-29 RS RS20230150A patent/RS63991B1/sr unknown
- 2016-07-29 US US15/223,434 patent/US10179819B2/en active Active
- 2016-07-29 MD MDE20180558T patent/MD3328888T2/ro unknown
- 2016-07-29 WO PCT/US2016/044732 patent/WO2017023761A1/en active Application Filing
- 2016-07-29 EA EA201890368A patent/EA038603B1/ru unknown
- 2016-07-29 HU HUE16748023A patent/HUE061419T2/hu unknown
- 2016-07-29 JP JP2018504829A patent/JP6975707B2/ja active Active
- 2016-07-29 PT PT167480235T patent/PT3328888T/pt unknown
- 2016-07-29 LT LTEPPCT/US2016/044732T patent/LT3328888T/lt unknown
- 2016-07-29 EP EP16748023.5A patent/EP3328888B1/en active Active
- 2016-08-01 AR ARP160102342A patent/AR106570A1/es unknown
-
2018
- 2018-11-23 HK HK18115045.3A patent/HK1255971A1/zh unknown
- 2018-11-30 US US16/205,917 patent/US11155633B2/en active Active
-
2021
- 2021-09-16 US US17/476,856 patent/US20210403595A1/en active Pending
- 2021-11-05 JP JP2021180839A patent/JP7271637B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255971A1 (zh) | 抗psma抗體、結合psma及cd3的雙特異性抗原結合分子及其用途 | |
| HUS2300011I1 (hu) | Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai | |
| IL289946A (en) | Bispecific antibodies against cd3 and cd20 | |
| ZA201901066B (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| IL259082A (en) | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof | |
| HK1249523A1 (zh) | 一種結合和egfrviii和cd3的雙特異性抗體構建物 | |
| HK1248250A1 (zh) | 連接中皮素和cd3的雙特異性抗體構建體 | |
| HK1249525A1 (zh) | 一種結合dll3和cd3的雙特異性抗體構建 | |
| ZA201701341B (en) | Bispecific her2 and cd3 binding molecules |